These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22223872)

  • 21. The frontline treatment of chronic myeloid leukemia in the chronic phase: current clinical decisions and future prospects for treatment.
    Jain N; O'Brien S
    Expert Rev Hematol; 2013 Oct; 6(5):575-86. PubMed ID: 24083594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up.
    Qin Y; Jiang B; Jiang Q; Jiang H; Li J; Zhang Y; Zhu H; Li L; Chen S; Liu Y; Huang X
    Ann Hematol; 2009 Jan; 88(1):37-41. PubMed ID: 18651143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations.
    Haznedaroglu IC
    Expert Opin Pharmacother; 2013 Oct; 14(15):2005-10. PubMed ID: 23984805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
    Zhou KS; Wang YY; Zhao YZ; Yi SH; Qian LS; Wang GR; Yu Z; Wang Y; Wang JX; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):208-12. PubMed ID: 20137149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
    Molica M; Colafigli G; Scalzulli E; Alunni Fegatelli D; Chiatamone Ranieri S; Rizzo L; Diverio D; Efficace F; Latagliata R; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1891-1904. PubMed ID: 31079264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case study for technology appraisal on the basis of surrogate outcomes evidence.
    Oriana C; Martin H; Toby P; Chris C; Ruth G; Claudius R; Rod T
    Value Health; 2013; 16(6):1081-90. PubMed ID: 24041359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib.
    Tao Z; Liu B; Zhao Y; Wang Y; Zhang R; Han M; Zhang L; Li C; Ru K; Mi Y; Wang J
    Leuk Res; 2014 Sep; 38(9):1030-5. PubMed ID: 24996976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose.
    Breccia M; Cannella L; Stefanizzi C; Latagliata R; Nanni M; Diverio D; Santopietro M; Federico V; Alimena G
    Hematol Oncol; 2010 Jun; 28(2):89-92. PubMed ID: 19728398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
    Shami PJ; Deininger M
    Leukemia; 2012 Feb; 26(2):214-24. PubMed ID: 21844872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia.
    Sacchi S; Kantarjian HM; Smith TL; O'Brien S; Pierce S; Kornblau S; Beran M; Keating MJ; Talpaz M
    J Clin Oncol; 1998 Mar; 16(3):882-9. PubMed ID: 9508169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surrogate end points for long-term outcomes in chronic myeloid leukemia.
    Akwaa F; Liesveld J
    Leuk Lymphoma; 2013 Oct; 54(10):2103-11. PubMed ID: 23383600
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
    Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A clinical study of treating 120 cases of adult chronic myelocytic leukemia with imatinib mesylate].
    Chen ZC; You Y; Zhu XM; Li QB; Li WM; Zou P
    Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):1003-6. PubMed ID: 18478917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.
    Nazha A; Kantarjian H; Jain P; Romo C; Jabbour E; Quintas-Cardama A; Luthra R; Abruzzo L; Borthakur G; Ravandi F; Pierce S; O'Brien S; Cortes J
    Haematologica; 2013 Nov; 98(11):1686-8. PubMed ID: 23812943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
    Goldberg SL; Cortes JE; Gambacorti-Passerini C; Hehlmann R; Khoury HJ; Michallet M; Paquette RL; Simonsson B; Zyczynski T; Foreman A; Abruzzese E; Andorsky D; Beeker A; Cony-Makhoul P; Hansen R; Lomaia E; Olavarria E; Mauro MJ
    Am J Hematol; 2017 Nov; 92(11):1214-1223. PubMed ID: 28815757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.
    Miyamura K; Ohnishi K; Ohtake S; Usui N; Nakaseko C; Fujita H; Fujisawa S; Sakura T; Okumura H; Iriyama N; Emi N; Fujimaki K; Honda S; Miyazaki Y; Naoe T
    Blood Adv; 2019 Feb; 3(3):312-319. PubMed ID: 30705033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.